MODERNA INC

NASDAQ: MRNA (Moderna, Inc.)

最近更新时间: 18 Feb, 12:10AM

43.93

1.70 (4.03%)

前收盘价格 42.23
收盘价格 42.37
成交量 10,420,148
平均成交量 (3个月) 11,778,720
市值 17,164,929,024
预期市盈率 (P/E Forward) 23.04
价格/销量 (P/S) 10.72
股市价格/股市净资产 (P/B) 2.42
52周波幅
22.28 (-49%) — 55.20 (25%)
利润日期 30 Apr 2026
营业毛利率 -105.67%
营业利益率 (TTM) -972.22%
稀释每股收益 (EPS TTM) -8.73
季度收入增长率 (YOY) -35.30%
总债务/股东权益 (D/E MRQ) 7.40%
流动比率 (MRQ) 4.22
营业现金流 (OCF TTM) -3.05 B
杠杆自由现金流 (LFCF TTM) -3.20 B
资产报酬率 (ROA TTM) -15.84%
股东权益报酬率 (ROE TTM) -29.34%

市场趋势

短期 中期
行业 Biotechnology (US) 看涨 混合的
Biotechnology (全球的) 看涨 混合的
股票 Moderna, Inc. 看涨 看跌

AIStockmoo 评分

-0.8
分析师共识 -1.5
内部交易活动 -1.5
价格波动 -5.0
技术平均移动指标 0.0
技术振荡指标 4.0
平均 -0.80

相关股票

股票 市值 DY P/E(TTM) P/B
MRNA 17 B - - 2.42
ERAS 4 B - - 1.62
NKTR 2 B - - 22.67
TYRA 2 B - - 6.34
HRMY 2 B - 8.92 1.99
PHAT 894 M - - -

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

部门 Healthcare
行业 Biotechnology
投资方式 Small Value
内部持股比例 7.28%
机构持股比例 73.67%
52周波幅
22.28 (-49%) — 55.20 (25%)
目标价格波幅
28.00 (-36%) — 69.00 (57%)
69.00 (Piper Sandler, 57.07%) 购买
34.00 (-22.60%)
28.00 (Morgan Stanley, -36.26%) 保留
平均值 38.14 (-13.18%)
总计 1 购买, 6 保留
平均价格@调整类型 39.56
公司 日期 目标价格 调整类型 价格@调整类型
Piper Sandler 23 Feb 2026 69.00 (57.07%) 购买 50.29
Evercore ISI Group 17 Feb 2026 35.00 (-20.33%) 保留 43.93
Goldman Sachs 17 Feb 2026 41.00 (-6.67%) 保留 43.93
RBC Capital 17 Feb 2026 30.00 (-31.71%) 保留 43.93
UBS 07 Jan 2026 34.00 (-22.60%) 保留 35.89
Jefferies 12 Dec 2025 30.00 (-31.71%) 保留 29.46
Morgan Stanley 12 Dec 2025 28.00 (-36.26%) 保留 29.46
名称 平均购买 ($) 平均卖出 ($) 总净额 总净值 ($)
HOGE STEPHEN - 50.29 -160,009 -8,046,853
累积净数量 -160,009
累积净值 ($) -8,046,853
累积平均购买 ($) -
累积平均卖出 ($) 50.29
名称 持有人 日期 类型 数量 价格 价值 ($)
HOGE STEPHEN 职员 23 Feb 2026 自动卖出 (-) 160,009 50.29 8,046,853
HOGE STEPHEN 职员 23 Feb 2026 执行期权 160,009 - -
日期 类型 细节
11 Feb 2026 CNBC Moderna says FDA refuses to review its application for experimental flu shot
04 Feb 2026 公告 Defiance Launches MRNX: The First Daily 2X Long ETF for Moderna, Inc.
30 Jan 2026 公告 Dr. David Berman to Join Moderna as Chief Development Officer
29 Jan 2026 公告 Moderna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic (mRNA-3927)
27 Jan 2026 公告 Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks
26 Jan 2026 公告 Moderna to Report Fourth Quarter 2025 Financial Results on Friday, February 13, 2026
20 Jan 2026 公告 Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Follow...
12 Jan 2026 公告 Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
05 Jan 2026 公告 Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine
18 Dec 2025 公告 CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate
17 Dec 2025 公告 Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference
15 Dec 2025 公告 EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA)
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2026 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票